Lord, Abbett & Co
SRPT icon

Lord, Abbett & Co’s Sarepta Therapeutics SRPT Stock Holding History

Lord, Abbett & Co’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-241,588
Closed -$29.3M – 583
2023
Q3 		$29.3M Sell
241,588
-160,978
-40% -$18.2M 0.11% 258
2023
Q2 		$46.1M Sell
402,566
-192,640
-32% -$24.8M 0.16% 190
2023
Q1 		$82M Sell
595,206
-464,366
-44% -$60.2M 0.3% 98
2022
Q4 		$137M Sell
1,059,572
-4,642
-0.4% -$538K 0.49% 46
2022
Q3 		$118M Buy
1,064,214
+740,283
+229% +$74.6M 0.43% 61
2022
Q2 		$24.3M Buy
323,931
+11,149
+4% +$820K 0.09% 302
2022
Q1 		$24.4M Sell
312,782
-492,198
-61% -$37.7M 0.07% 348
2021
Q4 		$72.5M Buy
+804,980
New +$68.8M 0.17% 194
2021
Q1 		– Sell
-273,268
Closed -$46.6M – 690
2020
Q4 		$46.6M Sell
273,268
-12,939
-5% -$1.92M 0.12% 262
2020
Q3 		$40.2M Sell
286,207
-3,046
-1% -$463K 0.13% 248
2020
Q2 		$46.4M Buy
289,253
+65,009
+29% +$8.85M 0.16% 203
2020
Q1 		$21.9M Buy
224,244
+48,052
+27% +$5.49M 0.1% 311
2019
Q4 		$22.7M Buy
176,192
+51,493
+41% +$5.2M 0.08% 373
2019
Q3 		$9.39M Sell
124,699
-198,854
-61% -$23.5M 0.03% 538
2019
Q2 		$49.2M Buy
323,553
+245
+0.1% +$29.8K 0.16% 227
2019
Q1 		$38.5M Sell
323,308
-8,066
-2% -$1.04M 0.13% 257
2018
Q4 		$36.2M Sell
331,374
-92,646
-22% -$11.6M 0.13% 248
2018
Q3 		$68.5M Sell
424,020
-112,213
-21% -$15.3M 0.19% 164
2018
Q2 		$70.9M Buy
536,233
+138,381
+35% +$13.1M 0.21% 145
2018
Q1 		$29.5M Sell
397,852
-139,422
-26% -$9.3M 0.09% 357
2017
Q4 		$29.9M Sell
537,274
-49,131
-8% -$2.6M 0.09% 365
2017
Q3 		$26.6M Buy
+586,405
New +$23.4M 0.08% 399
2016
Q4 		– Sell
-302,070
Closed -$18.6M – 950
2016
Q3 		$18.6M Buy
+302,070
New +$9.13M 0.06% 448
2016
Q2 		– Sell
-1,084,067
Closed -$21.2M – 921
2016
Q1 		$21.2M Buy
1,084,067
+352,359
+48% +$6.16M 0.07% 408
2015
Q4 		$28.2M Buy
731,708
+650,077
+796% +$21.1M 0.08% 359
2015
Q3 		$2.62M Sell
81,631
-109,683
-57% -$3.72M 0.01% 821
2015
Q2 		$5.82M Buy
+191,314
New +$3.91M 0.02% 747
2014
Q4 		– Sell
-695,278
Closed -$14.7M – 973
2014
Q3 		$14.7M Sell
695,278
-2,379,344
-77% -$53.7M 0.04% 547
2014
Q2 		$91.6M Sell
3,074,622
-207,931
-6% -$6.57M 0.21% 128
2014
Q1 		$78.9M Buy
3,282,553
+1,518,045
+86% +$38.7M 0.18% 161
2013
Q4 		$35.9M Sell
1,764,508
-1,059,417
-38% -$31.5M 0.08% 362
2013
Q3 		$133M Buy
2,823,925
+551,882
+24% +$21.3M 0.31% 76
2013
Q2 		$86.5M Buy
+2,272,043
New +$81.3M 0.2% 129

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Lord, Abbett & Co's SRPT Position: Q4 2023 in Review

Lord, Abbett & Co sold out of Sarepta Therapeutics (SRPT) in Q4 2023, closing a stake of 241,588 shares — an estimated $29.3M sold.

Lord, Abbett & Co first reported a position in SRPT in Q2 2013 and held it in 33 quarters. The position peaked at $137M in Q4 2022. 395 funds tracked by Wall St. Rank hold SRPT as of Q4 2023.

  • Lord, Abbett & Co reported no remaining Sarepta Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Lord, Abbett & Co sold 241,588 Sarepta Therapeutics shares in Q4 2023, an estimated $29.3M.
  • Lord, Abbett & Co first reported a position in Sarepta Therapeutics in Q2 2013 and held it in 33 quarters.
  • Lord, Abbett & Co's Sarepta Therapeutics position peaked at $137M in Q4 2022.
  • 395 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2023.

Based on Lord, Abbett & Co's 13F filing for Q4 2023, filed 12 Feb 2024.